Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Precocious and delayed puberty

Paediatrics and child health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Pubertal change with intracranial or tumour signs

Headache, morning vomiting, visual change, focal neurology, seizure, rapidly enlarging testicular or abdominal mass, or explosive virilisation can indicate a central nervous system or hormone-secreting tumour.

Action: Arrange urgent paediatric endocrine and acute assessment, neurological and gonadal examination, targeted hormones and tumour markers and appropriately timed brain, abdominal, pelvic or testicular imaging. Stabilise acute neurological or adrenal complications and protect the child from repeated unnecessary intimate examination.

Synopsis

Recognise puberty that starts too early, progresses too rapidly or fails to start, distinguish central activation from peripheral sex-steroid exposure and separate constitutional delay from gonadal or hypothalamic-pituitary disease using growth, staging and ordered endocrine investigation.

  • Precocious puberty means secondary sexual development before 8 years in girls or 9 years in boys; rate, sequence, growth acceleration and neurological symptoms determine urgency as well as age.
  • Delayed puberty is absence of breast development by 13 years in girls or testicular enlargement by 14 years in boys; absent menarche by 15 years or more than three years after breast onset also requires assessment.
  • True central puberty follows the normal sequence with growth acceleration and advanced bone age; isolated early breast or pubic-hair development can be benign but needs trajectory review.
  • Rapid virilisation, vaginal bleeding without breast progression, testicular asymmetry or Cushingoid features suggests peripheral hormone production or exposure rather than simple early central puberty.
  • First-line assessment documents serial height velocity, Tanner stage, testicular volume, body proportions, BMI, neurological findings, chronic disease, nutrition, exercise, medicines and family pubertal timing.
  • Bone age estimates sex-steroid exposure and remaining height potential. Basal LH, FSH and estradiol or testosterone are timed and interpreted using paediatric, pubertal and assay-specific ranges.
  • A GnRH stimulation test can confirm central activation when basal results and progression are unclear; random sex hormones or adult laboratory ranges create misleading conclusions.
  • Brain MRI is urgent for neurological signs and usually indicated in boys with central precocious puberty and in very young girls or atypical rapid progression according to specialist assessment.
  • Long-acting GnRH agonist can pause central precocious puberty when progression threatens height or causes important psychosocial burden; treat peripheral puberty by correcting the underlying adrenal, gonadal, tumour or exposure source.
  • Constitutional delay is a diagnosis supported by healthy slow tempo, delayed bone age and family history after exclusion of chronic disease; high gonadotrophins indicate gonadal failure, while low or normal gonadotrophins require hypothalamic-pituitary and functional assessment.

Key red flags

Pubertal signs with headache, vomiting, visual loss, seizure or focal deficit requires urgent intracranial evaluation.

Precocious puberty in a boy is more likely to have an identifiable pathological cause and needs prompt specialist work-up.

Rapid virilisation, clitoral enlargement, deep voice or very rapid growth suggests substantial androgen exposure or tumour.

Vaginal bleeding without expected breast progression or a palpable abdominal mass requires urgent peripheral-cause assessment.

A hard or asymmetric testis, testicular pain or mass needs urgent ultrasound and tumour-aware referral.

Delayed puberty with anosmia, polyuria, visual symptoms or multiple pituitary features suggests central hormone deficiency.

Weight loss, restrictive eating, excessive exercise or chronic diarrhoea can suppress puberty and requires systemic and safeguarding-aware care.

Neurological puberty cause

Headache, vomiting, visual or focal signs accompanying early or stalled puberty suggests intracranial pathology requiring urgent imaging.

Investigation priorities

01
First-line growth and Tanner assessmentFirst stepFirst line

Document onset, tempo, sequence, testicular volume, height velocity, proportions and pubertal stage accurately.

Management branches

Early pubertyDefine central, peripheral or isolated change

Secondary sexual features appear before 8 years in a girl or 9 years in a boy.

  1. Record sequence, rate, exposures, neurological symptoms, height velocity, Tanner stage and testicular or pelvic findings.
  2. Obtain bone age and mechanism-directed basal hormones, using stimulation testing when central activation remains uncertain.
  3. Arrange risk-based brain or gonadal imaging and observe only genuinely non-progressive isolated variants with a dated review.

Key medicines

Long-acting GnRH agonistGive the selected licensed leuprorelin, triptorelin or histrelin formulation at its product-specific paediatric dose and interval, commonly every 4 weeks or as a longer-acting depot, through the endocrine service.Explain initial bleeding or symptom flare, verify suppression and growth response, manage injection or implant issues and do not use as sole treatment for peripheral hormone production.
Low-dose pubertal induction hormoneUse a specialist stepwise regimen of low-dose testosterone for boys or low-dose oestradiol for girls, increasing gradually over roughly two to three years when permanent deficiency requires physiological pubertal induction.Avoid starting at adult replacement doses, review bone age and growth, add progestogen after adequate oestrogen exposure when indicated and discuss fertility separately.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • BSPED clinical guidelinesUK paediatric endocrine guidance and professional resources for puberty and gonadal disorders.
  • NHS early or delayed pubertyUK thresholds, common presentations, causes, assessment and patient-facing treatment overview.
  • RCPCH UK-WHO growth chartsGrowth and pubertal plotting used to interpret tempo, acceleration and delayed maturation.
  • BNF for ChildrenLicensed GnRH agonist and sex-steroid formulations, administration intervals and medicine safety.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom